Literature DB >> 14613025

Dysregulation of cellular signaling by HER2/neu in breast cancer.

Binhua P Zhou1, Mien-Chie Hung.   

Abstract

Human epidermal growth factor receptor-2 (HER2/neu; erbB2) belongs to a family of four transmembrane receptor tyrosine kinases involved in signal transduction pathways that regulate cell growth and proliferation. Amplification or overexpression of HER2/neu occurs in about 30% of human breast and ovarian cancers and is associated with a poor clinical outcome, including short survival time and short time to relapse. Recent advances in our understanding of HER2/neu signaling pathways have greatly increased our knowledge of breast cancer tumorigenesis and have provided new targets for treating breast and ovarian tumors that overexpress HER2/neu. This review will focus on the signaling network mediated by HER2/neu in breast cancer and discuss our understanding of these pathways, which seem to be particularly important in mediating cell survival and growth under a wide variety of circumstances in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613025     DOI: 10.1053/j.seminoncol.2003.08.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  30 in total

Review 1.  The ErbB2 signaling network as a target for breast cancer therapy.

Authors:  Ali Badache; Anthony Gonçalves
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

Review 2.  Her-2 targeted therapy: beyond breast cancer and trastuzumab.

Authors:  Keith T Flaherty; Marcia S Brose
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

3.  Down-regulation of vascular endothelial growth factor expression by anti-Her2/neu single chain antibodies.

Authors:  Foroogh Nejatollahi; Mahdi Asgharpour; Mansooreh Jaberipour
Journal:  Med Oncol       Date:  2011-01-26       Impact factor: 3.064

4.  Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.

Authors:  Wilko Weichert; Glen Kristiansen; Klaus-Jürgen Winzer; Mathias Schmidt; Volker Gekeler; Aurelia Noske; Berit-Maria Müller; Silvia Niesporek; Manfred Dietel; Carsten Denkert
Journal:  Virchows Arch       Date:  2005-03-23       Impact factor: 4.064

5.  CKS1BP7, a Pseudogene of CKS1B, is Co-Amplified with IGF1R in Breast Cancers.

Authors:  Yansong Liu; Wei Wang; Yan Li; Feifei Sun; Jiaxiang Lin; Li Li
Journal:  Pathol Oncol Res       Date:  2017-04-24       Impact factor: 3.201

6.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

7.  Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.

Authors:  Luigi Aurisicchio; Daniela Peruzzi; Gloria Koo; Wei-Zen Wei; Nicola La Monica; Gennaro Ciliberto
Journal:  Hum Gene Ther       Date:  2013-12-21       Impact factor: 5.695

Review 8.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

Review 9.  A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.

Authors:  Ikuo Sekine; Chikako Shimizu; Kazuto Nishio; Nagahiro Saijo; Tomohide Tamura
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

10.  Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.

Authors:  Gulisa Turashvili; Samuel Leung; Dmitry Turbin; Kelli Montgomery; Blake Gilks; Rob West; Melinda Carrier; David Huntsman; Samuel Aparicio
Journal:  BMC Cancer       Date:  2009-05-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.